Literature DB >> 9815220

Standardization of the experimental model of Haemophilus ducreyi infection in human subjects.

J A Al-Tawfiq1, A C Thornton, B P Katz, K R Fortney, K D Todd, A F Hood, S M Spinola.   

Abstract

Human volunteers were challenged with Haemophilus ducreyi. Twenty subjects were inoculated with 2 doses (approximately 30 cfu) of live and 1 dose of heat-killed bacteria at 3 sites on the arm. Eight subjects were assigned to biopsy 1 or 4 days after inoculation, and 12 were biopsied after they developed a painful pustular lesion or were followed until disease resolved. Papules developed at 95% of 40 sites infected with live bacteria (95% confidence interval [CI], 83. 1%-99.4%). In 24 sites followed to end point, 27% of the papules resolved, 69% (95% CI, 47.1%-86.6%) evolved into pustules, and 4% remained at the papular stage. Recovery rates of H. ducreyi from surface cultures ranged from 13% to 41%. H. ducreyi was recovered from biopsies of 12 of 15 pustules and 1 of 7 papules, suggesting that H. ducreyi replicates between the papular and pustular stages of disease.

Entities:  

Mesh:

Year:  1998        PMID: 9815220     DOI: 10.1086/314483

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  74 in total

1.  Haemophilus ducreyi associates with phagocytes, collagen, and fibrin and remains extracellular throughout infection of human volunteers.

Authors:  M E Bauer; M P Goheen; C A Townsend; S M Spinola
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Transcription of candidate virulence genes of Haemophilus ducreyi during infection of human volunteers.

Authors:  R E Throm; S M Spinola
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 3.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Binding of Haemophilus ducreyi to extracellular matrix proteins.

Authors:  M E Bauer; S M Spinola
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  Sialylation of lipooligosaccharides is dispensable for the virulence of Haemophilus ducreyi in humans.

Authors:  Stanley M Spinola; Wei Li; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Barry P Katz; Robert S Munson
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

6.  Expression of Haemophilus ducreyi collagen binding outer membrane protein NcaA is required for virulence in swine and human challenge models of chancroid.

Authors:  Robert A Fulcher; Leah E Cole; Diane M Janowicz; Kristen L Toffer; Kate R Fortney; Barry P Katz; Paul E Orndorff; Stanley M Spinola; Thomas H Kawula
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

7.  Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection.

Authors:  Stanley M Spinola; Cliffton T H Bong; Andrew L Faber; Kate R Fortney; Stacy L Bennett; Carisa A Townsend; Beth E Zwickl; Steven D Billings; Tricia L Humphreys; Margaret E Bauer; Barry P Katz
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  The LspB protein is involved in the secretion of the LspA1 and LspA2 proteins by Haemophilus ducreyi.

Authors:  Christine K Ward; Jason R Mock; Eric J Hansen
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

9.  Trimeric autotransporter DsrA is a major mediator of fibrinogen binding in Haemophilus ducreyi.

Authors:  William G Fusco; Christopher Elkins; Isabelle Leduc
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

10.  Haemophilus ducreyi SapA contributes to cathelicidin resistance and virulence in humans.

Authors:  Kristy L B Mount; Carisa A Townsend; Sherri D Rinker; Xiaoping Gu; Kate R Fortney; Beth W Zwickl; Diane M Janowicz; Stanley M Spinola; Barry P Katz; Margaret E Bauer
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.